Drug Profile
BMS 986090
Alternative Names: Anti-CD40 dab; Anti-CD40 monoclonal antibody - BMS; BMS-986090Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Immunological-disorders(In volunteers) in USA (IV, Infusion)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Immunological-disorders(In volunteers) in USA (SC, Injection)
- 30 Mar 2016 Bristol-Myers Squibb terminates a phase I trial in healthy volunteers in USA (NCT02079480)